Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 25;13(1):1376.
doi: 10.1038/s41598-023-28405-6.

Utilisation of exome sequencing for muscular disorders in Thai paediatric patients: diagnostic yield and mutational spectrum

Affiliations

Utilisation of exome sequencing for muscular disorders in Thai paediatric patients: diagnostic yield and mutational spectrum

Sarinya Summa et al. Sci Rep. .

Abstract

Muscular dystrophies and congenital myopathies are heterogeneous groups of inherited muscular disorders. An accurate diagnosis is challenging due to their complex clinical presentations and genetic heterogeneity. This study aimed to determine the utilisation of exome sequencing (ES) for Thai paediatric patients with muscular disorders. Of 176 paediatric patients suspected of genetic/inherited myopathies, 133 patients received a molecular diagnosis after performing conventional investigations, single gene testing, and gene panels. The remaining 43 patients from 42 families could be classified into three groups: Group 1, MLPA-negative Duchenne muscular dystrophy (DMD) with 9 patients (9/43; 21%), Group 2, other muscular dystrophies (MD) with 18 patients (18/43; 42%) and Group 3, congenital myopathies (CM) with 16 patients (16/43; 37%). All underwent exome sequencing which could identify pathogenic variants in 8/9 (89%), 14/18 (78%), and 8/16 (50%), for each Group, respectively. Overall, the diagnostic yield of ES was 70% (30/43) and 36 pathogenic/likely pathogenic variants in 14 genes were identified. 18 variants have never been previously reported. Molecular diagnoses provided by ES changed management in 22/30 (73%) of the patients. Our study demonstrates the clinical utility and implications of ES in inherited myopathies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Patient enrolment workflow.
Figure 2
Figure 2
Molecular diagnoses by disease group. Molecular diagnoses using exome sequencing were established in 70% of the patients. The number of patients is given in parentheses.

Similar articles

Cited by

References

    1. Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381:845–860. doi: 10.1016/S0140-6736(12)61897-2. - DOI - PubMed
    1. North KN, et al. Approach to the diagnosis of congenital myopathies. Neuromuscul. Disord. 2014;24:97–116. doi: 10.1016/j.nmd.2013.11.003. - DOI - PMC - PubMed
    1. Benarroch L, Bonne G, Rivier F, Hamroun D. The 2021 version of the gene table of neuromuscular disorders (nuclear genome) Neuromuscul. Disord. 2020;30:1008–1048. doi: 10.1016/j.nmd.2020.11.009. - DOI - PubMed
    1. Valencia CA, et al. Comprehensive mutation analysis for congenital muscular dystrophy: A clinical PCR-based enrichment and next-generation sequencing panel. PLoS ONE. 2013;8:e53083. doi: 10.1371/journal.pone.0053083. - DOI - PMC - PubMed
    1. Bohm J, et al. An integrated diagnosis strategy for congenital myopathies. PLoS ONE. 2013;8:e67527. doi: 10.1371/journal.pone.0067527. - DOI - PMC - PubMed

Publication types